Oruka Therapeutics
ORKA
13 hedge funds and large institutions have $694K invested in Oruka Therapeutics in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
8% more funds holding
Funds holding: 12 → 13 (+1)
0% more ownership
Funds ownership: 0.07% → 0.07% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
39% less capital invested
Capital invested by funds: $1.13M → $694K (-$439K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$85.1K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$9.93K |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
+$620 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$57K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.12K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$868 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $273K | +$85.1K | +686 | +22% |
|
|
TCM
2
Tekla Capital Management
Boston,
Massachusetts
| $271K | – | – | – |
|
|
3
Acadian Asset Management
Boston,
Massachusetts
| $51K | +$9.93K | +80 | +13% |
|
|
ACP
4
Aveo Capital Partners
Englewood,
Colorado
| $31K | – | – | – |
|
|
PAM
5
Panagora Asset Management
Boston,
Massachusetts
| $28K | -$868 | -7 | -2% |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| $17K | -$1.12K | -9 | -4% |
|
7
Geode Capital Management
Boston,
Massachusetts
| $16K | – | – | – |
|
8
Northern Trust
Chicago,
Illinois
| $5K | – | – | – |
|
9
Morgan Stanley
New York
| $1K | – | – | – |
|
|
GWMIA
10
Global Wealth Management Investment Advisory
Fort Lauderdale,
Florida
| $1K | +$868 | +7 | New |
|
|
VF
11
Virtu Financial
New York
| – | -$57K | -464 | Closed |
|
|
AG
12
Advisor Group
Phoenix,
Arizona
| – | +$620 | +5 | New |
|
ORKA Hedge Fund Activity: Q4 2018 in Review
13 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q4 2018, worth a combined $694K — down 39% from $1.13M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ORKA positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $85.1K. The largest seller was Virtu Financial, exiting entirely with an estimated $57K sold.
- 13 institutional investors held Oruka Therapeutics (ORKA) as of Q4 2018, up from 12 in Q3 2018.
- Funds reported $694K of Oruka Therapeutics stock for Q4 2018, down 39% quarter-over-quarter.
- 2 funds opened new Oruka Therapeutics positions in Q4 2018 and 1 closed out, a net change of +1 holder.
- The largest Oruka Therapeutics buyer in Q4 2018 was Renaissance Technologies, an estimated $85.1K added.
- The largest Oruka Therapeutics seller in Q4 2018 was Virtu Financial, an estimated $57K sold.
Based on aggregated 13F filings for Q4 2018.